Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA

ROCKVILLE, Md., Oct.29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX)
a clinical-stage vaccine company, announced today that its abstract has been
selected for poster presentation at the Infectious Diseases Society of America
(IDSA) 47th Annual meeting being held in Philadelphia, Pennsylvania from
October 29 - November 1, 2009.

Poster presentation: "Safety and Immunogenicity of a Recombinant Trivalent
Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults", Penny
Heaton, M.D., Maria Allende, M.D., Kathy Lenhard, R.N., Mike Massare, PhD.,
and Mark Wolff, PhD. Saturday October 31, 2009 12:30 pm to 2:00 pm.,
Pennsylvania Convention Center, Poster Hall A.

About the 47th Annual Meeting of the IDSA
This conference will showcase abstract presentations containing outstanding,
noteworthy science; and expanded roster of challenging interactive sessions;
symposia on management of difficult pathogens, such as MRSA, Clostridium
difficle, and drug-resistant mycobacteria, gram-negative bacillia and fungi;
and the promises and challenges of new vaccines. The Special Plenary Session
and Named Lectures will highlight important advancements as well as challenges
in the world of infectious diseases. Additional information is available at
www.idsociety.org.

About Novavax
Novavax, Inc. is a clinical-stage biotechnology company, creating novel
vaccines to address a broad range of infectious diseases worldwide, including
H1N1, using advanced proprietary virus-like-particle (VLP) technology. The
company produces potent VLP -based recombinant vaccines utilizing new and
efficient manufacturing approaches. Novavax is committed to using its VLP
technology to create country-specific vaccine solutions. The Company has
formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to
develop and manufacture vaccines, biological therapeutics and diagnostics in
India. Additional information about Novavax is available on the company's
website: www.novavax.com

SOURCE Novavax, Inc.

Tricia J. Richardson of Novavax, Inc. +1-240-268-2031